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Abstract. The binding activity of the AP-1 FOS/JUN 
complex to a negative regulatory element on the c-myc 
promoter was investigated and correlated with events 
characteristic of terminal differentiation of HMBA-induced 
mouse erythroleukemic cells. It is suggested that the altered 
AP-1 activity that was found upon induction of the erythroid 
differentiation may contribute to the late decline in c-myc 
mRNA. 
Introduction 
The c-myc proto-oncogene encodes for two highly conserved 
nuclear phosphoproteins p62 and p64 involved in cellular 
proliferation and differentiation (1). c-myc expression may be 
controlled at at least four levels (reviewed in ref. 2). First, at 
the level of transcription initiation through four separate 
RNA start sites (PO, PI, P2 and P3). Furthermore, a block in 
transcriptional elongation has been observed during 
differentiation of HL60 human promyelocytic leukemia (3) 
and MEL cells (4), while mRNA stability may be another 
important mechanism of regulation as demonstrated for 
murine plasmacytomas (5). Finally, expression of the murine 
c-myc gene appears also to be controlled at the level of 
mRNA translation (6). 
Transcriptional regulation of c-myc is extremely complex 
and is modulated by both positive and negative c/s-acting 
regulatory elements. The role of regulatory elements located 
within 5' flanking sequences and within exon I of c-myc are 
not only important for the regulation of transcription from 
PO, PI and P2 (7-11) but also for premature termination of 
transcripts (12) and translational control (6). 
Friend leukemic cells (FLC) are mouse erythroid 
precursor cells blocked at an early stage of erythroid 
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differentiation (13). When these cells are exposed to HMBA 
or a variety of other chemicals, they reinitiate a program of 
erythroid differentiation, culminating in hemoglobin 
synthesis and terminal cell division (13). During the 
differentiation process, a biphasic change in c-myc and c-myb 
mRNAs is observed (14,15). Alterations in c-fos, K-ras and 
p53 gene expression have also been reported in some but not 
all FLC lines (15,16). 
The c-fos oncogene is known to participate in 
transcriptional regulation through formation of a c-fos:c-jun 
heterodimer protein known as the AP-1 complex (for a 
review see ref. 17). The AP-1 complex has been reported to 
participate in the process of differentiation ( 18) and may also 
control the expression of genes involved in cellular 
proliferation (17). Since an AP-1 binding site has been found 
within the c-myc promoter (19), it was of interest to study the 
levels of AP-1 complex bound to that region during HMBA-
induced erythroid differentiation. Our data suggests that 
differential AP-1 binding may represent a possible 
mechanism (or part of a mechanism) which regulates c-myc 
expression during this process. 
Materials and methods 
Cell lines and culture conditions. The F412B2TK mouse 
erythroleukemic (Friend) cells and the HeLa cell line used in 
this study, were continuously maintained in RPMI-I640 
(Gibco) with 50 μg/ml streptomycin and 300 μg/ml 
penicillin, supplemented with 10% Fetal Calf Serum (Flow), 
at 37°C in a 5% C0 2 atmosphere. 
Erythroid differentiation was achieved by exposing FLC 
to 3 mM HexaMethyleneBisAcetamide (HMBA, Sigma) 
dissolved in water. 
Hemoglobin quantitation. Hemoglobin content of induced 
and non-induced cells was estimated using the method of 
Rutherford (20), as modified. 
107 cells exposed to 3 mM HMBA for various time 
intervals (0, 24, 48, 72, 96 and 120 h) were centrifuged (700 
χ g, 5 min, 4°C) and washed with PBS twice. After removing 
the supernatant, the pellet was lysed in 1 ml distilled water 
and two cycles of freeze (-70°C) and thaw (37°C). 
Centrifugation at 12000 χ g for 5 min at 4°C gave a clear 
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supernatant which was used immediately for photometric 
estimation of hemoglobin at wavelength range of 405-420 nm 
and quantitation at 414 nm, in a LKB 4054 spectrophotometer. 
Extraction of total RNA and Northern blot analysis. RNA 
extracts from differentiated and non-differentiated cells were 
prepared as described by Sambrook et al (21 ). 
Briefly, cells were harvested (700 χ g, 5 min, 4°C). 
washed with PBS and the pellet was then lysed in 
guanidinium thiocyanate solution. After phenol/chloroform/ 
isoamylalcohol extraction, the aqueous phase was removed, 
an equal volume of isopropanol was added and left for 1 h at 
-20°C. Centrifugation at 12,000 χ g for 25 min at 4°C gave a 
RNA pellet which was rinsed in 70% ethanol, dried in 
vacuum and resuspended in RNase-free water. We estimated 
the RNA concentration photometrically at 260 nm. 
12 μg of each RNA sample were incubated with a solution 
containing 2 μΐ 5 χ MOPS, 3.5 μΐ formaldehyde and 10 μΐ 
formamide in a final volume of 20 μ], at 65°C for 15 min. 
Samples were then loaded in a 1 % formaldehyde gel and 
run for approximately 4 h at 80V in a MOPS/formaldehyde 
running buffer. 
For Northern blotting we followed the Hybond-N+ 
protocol (Amersham) using 20 X SSPE buffer. After blotting, 
RNA was fixed by baking the membrane at 80°C for 2 h. 
Pre-hybridization with 5 X SSPE, 5 χ Denhardt's solution 
50 % formamide and 0.5% (w/v) SDS for 6 h in 42°C, was 
followed by overnight hybridization. The probes used were 
the 7.0 Kb EcoRI/EcoRI fragment of plasmid pBRMßG-6 
carrying the mouse ß-globin gene, the 1.4 Kb Clal/EcoRI 
fragment of plasmid pMC41-3RC, carrying the third exon 
(EHI) of the human c-myc gene and the 3 Kb Xhol/Ncol 
fragment of plasmid pc-fos, carrying the human c-fos gene. 
Mouse ß-actin DNA was a gift from Dr E. Gonos (Ludwig 
Institute for Cancer Research, London, UK). All DNA-
inserts were labelled with , :P dCTP (Amersham) using the 
random primed DNA labelling kit of Boehringer Mannheim. 
The membranes were finally washed twice in 2 X SSPE, 
0.1% SDS in room temperature for 30 min, twice in 1 X 
SSPE, 0,1% SDS for 20 min at 42°C and once in 0.5 X 
SSPE, 0.1% SDS in 42°C for 15 min, followed by exposure 
to X-ray film (Fuji) with an intensifying screen. 
Preparation of nuclear extracts. Nuclear extracts from 
F412B2TK" and HeLa cells were prepared as previously 
described (22). Briefly, cells were harvested (700 χ g, 5 min, 
4°C), washed with PBS and dried. The cell pellets were 
homogenised with a B-type dounce homogenizer in 
hypotonic buffer (25 mM Tris.HCl pH=7.5, 5 mM KCl, 0.5 
mM MgCL, 0.5 mM dithiothreitol (DTT) and 0.5 mM 
PMSF), centrifuged at 2,000 χ g, washed three times with 
isotonic buffer (25 mM Tris.HCl pH=7.5, 5 mM KCl, 0.5 
mM MgCL, 0.1 M surcose, 0.5 mM DTT and 0.5 mM 
PMSF), and resuspended in nuclei extraction buffer (25 mM 
Tris.HCl pH=7.5, 1 mM EDTA. 0.1% Triton X-100, 0.5 m M 
DTT, 0.5 mM PMSF and 0.6 M KCl). Nuclei were inverted 
slowly for 30 min and the extract clarified by centrifugation 
at 2.5 χ IO4 g for 60 min at 4°C. Nuclear extracts were stored 
at -70°C. Protein estimations were performed using Biorad 
Protein Assay (Biorad). 
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Figure 1. Regulatory elements and transcription factor binding sites on the 
c-myc promoter (2.8-11 ). The AP-1 binding site is located whithin an NRE 
domain of c-myc promoter ( 19). 
Synthesis of oligonucleotides and gel retardation assays. The 
E3AP1 oligonucleotide 5'-CCGAAGTTCAGATGA 
CTAACTCAGGG-3' representing the region between 
nucleotides -81 and -103 of the EIA inducible E, promoter 
(23) was used as control for AP-1 binding activity. The 
mvcAP-1 oligonucleotide 5'-CCTGCGATGATTTATAC 
TCACAGG-3' contains the AP-1 binding site of the NRE 
domain of the human c-myc promoter (-342 to -313) (19) 
(Fig. 1). Both oligonucleotides were synthesized on an 
Applied Biosystems 381A DNA synthesizer. 
Single stranded complementary oligonucleotides were 
annealed, end-labelled using γ-32Ρ-ΑΤΡ (Amersham) and T4 
polynucleotide kinase (Boehringer) and run on a 8% 
Polyacrylamide gel to test that the annealing had worked. 
The binding reaction mixture contained 10 mM Hepes 
(pH=7.9), 0.2 mM EDTA, 94 mM NaCl, 0.1 mM PMSF, 0.1 
ng/ml BSA, 4% glycerol, 3 μg poly(dl-dC) (Pharmacia), 0.2-
1.0 ng 3 2P labelled DNA and 20 μg nuclear extracts (exept 
when otherwise indicated). Incubation was on ice for 30 min. 
Then, reaction mixtures were loaded onto a 5% 
Polyacrylamide gel (29:1 acrylamide: N,N'-methylene 
bisacrylamide, Serva). Gels were run at 4°C in 0.55 X TBE, 
dried and exposed to X-ray film for autoradiography (Fuji). 
FOS 388 and JUN 948 antibodies used in this study were 
a generous gift of Dr D.A.F. Gillespie (Beatson Institute for 
Cancer Research, Glasgow, UK). 
Assay for cell proliferation. Cell proliferation was estimated 
using the rapid colorimetrie assay of Mossman (24) as 
previously described (25). In brief, 10 μΐ of MTT [3-(4,5-
dimethylthiazol 2-yl)-2,5 - diphenyl tetrazolium bromide] 
(Sigma) in PBS were added to 100 μΐ complete medium in a 
Costar 96 well plate containing F412B2TK cells exposed to 
3 mM HMBA for various lengths of time (0, 24, 48, 72, 96 
and 120 h). After incubation for 4 h at 37°C, 110 μΐ of 0.04 
HCl in isopropanol were added. Optical Density (O.D) was 
recorded at 540 nm using a Titertek Flow Micro ELIZA 
reader. 
Results 
Exposure of mouse erythroleukemic cells to HMBA results 
in alteration of expression of several genes, the most 
characteristic of which are the globin genes. In order to 
examine whether the differentiated process had occurred in 
our system, we performed Northern blot analysis of total 
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Figure 2. Relative levels of ß-globin (a), c-myc (b). c-fos (c) and ß-actin (d) 
mRNAs during HMBA induction of F412B2TK- cells. Total RNA isolation. 
Northern blot analysis and hybridization probes are described in Materials 
and methods. The same filter was used for the four hybridizations. 
Autoradiographic exposure time was approximately 36 h. The positions of 
18S and 28S ribosomal RNAs in the gel. visualized by ethidium bromide 
staining, are indicated in the figure. Densitometrie analysis of the 
autoradiograms. normalized to ß-actin. verified the continuous down-
regulation of c-myc and the increased levels of ß-globin and c-fos mRNA. 
Two independent experiments were performed. 
RNA isolated from differentiated (days 1 to 5) and non-
differentiated cells. As depicted in Fig. 2a. a dramatic 
increase in ß-globin expression was observed during the 
differentiation process, followed by hemoglobin production. 
Hemoglobin gives a characteristic peak in 413-414 nm (20) 
which becomes obvious as early as the second day of 
differentiation (Fig. 3). No significant differences in globin 
gene expression were observed between days 4 and 5 after 
the initiation of drug exposure. Growth arrest, which is 
another characteristic of finally differentiated cells was 
demonstrated by a rapid cell proliferation assay for various 
times intervals (0. 24, 48. 72. 96 and 120 h) (Fig. 4). 
c-myc is one of the oncogenes that respond early to 
induction of differentiation and presents a marked decrease 
in its expression during the final steps of differentiation of 
FI.C cells, as depicted in Fig. 2b. The c-fos oncogene is up-
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Figure 3. Photometric estimation of hemoglobin accumulation during 
differentiation of FL cells. Absorption values at 414 nm after exposure of 
F412B2TK- cells to 3 m M HMBA for 0, 24. 48. 72. 96 and 120 h. Mean 
values from 4 independent experiments are given. Standard deviation is 
depicted as vertical bars. 
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Figure 4. Cell proliferation of differentiating and control F412B2TK" cells. 
Mean values from 3 independent experiments are given. Standard deviation 
of 9 values for each point is depicted as vertical bars. 
regulated as early as 24 h post-induction but its levels remain 
constant thereafter (Fig. 2c). 
We further investigated the alteration in AP-1 levels 
bound to AP-1 site of c-myc promoter. When crude extracts 
from HeLa cells were incubated with labelled wycAP-1 oligo 
(Fig. 1), three protein-DNA complexes formed (a, b and c. 
Fig. 5, lanes 5,6) which is consistent with previous reports 
(19,26). On the contrary, when the same extracts were 
incubated with E3AP1 oligo, only the two, slower migrating 
a, b complexes were formed (lanes 1 and 2, Fig. 5). A similar 
pattern of protein binding was observed with extracts from 
Friend leukemic cells (FLC) F412B2TK" (Fig. 5, lanes 3.4 
and 7,8). 
Among the three protein-wvc oligo complexes, only the b 
complex has been shown to be an AP-1 (FOS/JUN) (19). 
Indeed, in gel retardation experiments. FOS and JUN 
antibodies eliminated the b-band in extracts of both 
differentiated and finally differentiated (day 4) FLC (Fig. 6, 
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Figure 5. Binding of nuclear factors from HeLa and F412B2TK" cells to 
Ε,ΑΡΙ and mvcAP-l oligo. Only the b complex has been shown to be a 
FOS/JUN (AP-l) protein (see text). 
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Figure 7. Altered protein-binding activity on mycAP-1 oligo was observed 
during differentiation of F412B2TIC cells with 3 mM HMBA. 
lanes 6-11). Competition assay with excess (200X) of Ε,ΑΡΙ 
showed a decrease in the formation of protein-DNA complex 
b, while both protein-DNA complexes (b and c) were 
inhibited in the presence of 200X excess of myc AP-1 oligo 
(Fig. 6, lanes 3-5). 
Finally, we used end-labelled myc AP-1 oligo to study the 
binding activity of AP-1 during HMBA-induced 
differentiation of FLC. Cell extracts from FLC induced with 3 
mM HMBA or non-induced were incubated with the myc AP-\ 
probe. As shown in Fig. 7, a dramatic increase in AP-1 
binding is observed during the first 72 h, followed by a drop 
at 96 and 120 h post-induction. Similar results were obtained 
in two other independent experiments, while in another, the 
peak of binding was observed on day 2 (48 h) after induction, 
probably reflecting cell-cycle effects. 
In order to further certify that the altered protein binding 
was indeed AP-1, we repeated the experiment described 
above, using E3AP-1 probe instead of mycAP-1. As shown in 
Fig. 8, the same binding pattern was observed, except that 
there was no formation of the complex c. 
Figure 6. Effect of competitors (lanes 3-5) and FOS and JUN antibodies 
(lanes 6-11) on c-myc DNA-protein complexes in a gel retardation assay. 
Extracts from both undifferentiated and finally differentiated (day 4) FL cells 
were used for the study of AP-1. FOS 388 antibody eliminates both b and c 
bands while JUN 948 inhibits only the binding of the b (API ) complex. 
Discussion 
HMBA-induced differentiation of mouse erythroleukemic 
(Friend) cells is a multiple-stage process involving an early 
latent period during which metabolic changes can be detected, 
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Figure 8. Protein extracts from differentiated and undifferentiated Friend 
cells were incubated with E,AP-l and run in a gel retardation assay. A 
similar binding effect, compared with wivcAP-l oligo. was observed except 
that the c-complex did not bind. 
although cells are not yet committed irreversibly to 
differentiate, that is, they can not undergo the program of 
terminal cell division and gene expression upon removal of 
HMBA from the culture. In the presence of HMBA more 
than 90% of the cells are committed after 48-60 h exposure 
to HMBA (15). Induction of globin genes is observed after 
24 h (Fig. 2a and 3) while irreversible cessation of 
proliferation occurs 72 to 96 h post-induction (Fig. 4). 
Nuclear oncogenes, especially c-myc and c-myb, show a 
biphasic change in their expression, which may be correlated 
with the commitment of FLC to differentiate. Constitutive c-
myc expression blocks differentiation but not commitment 
(27), probably by interfering at a point prior to or close to the 
commitment (28). Taking also into account that the late but 
not the early decline in mRNA, coincides well with the 
change of protein level (29), commitment may require 
regulatable expression of c-myc whereas induction to 
differentiation may require only the late decline in c-myc 
mRNA (28). The mechanism of c-myc down regulation in 
both cases is complicated and both transcriptional and post-
transcriptional control have been reported (4,16,30). Since a 
promoter-driven regulation has been suggested for c-myc 
expression during the differentiation of F412B2(TK ) Friend 
erythroleukemia cells (16), it was of interest to study the 
binding activity of FOS/JUN (AP-1) complex on a c-myc 
negative regulatory element found to contain an AP-1 
binding site (19). The NRE domain of c-myc has been 
previously shown to be important for c-myc expression after 
anthracycline (25) and platinum compound (31) exposure of 
Friend cells. 
Among the three factors bound to the NRE domain of c-
myc, the AP-1 complex and the ubiquitous octamer-binding 
factor have been identified (Fig. 5, bands b and a, 
respectively) (19,26). These two complexes bind to highly 
overlapping segments of the c-myc sequence but do not 
cross-compete (26). In agreement with these experimental 
data, we observed no alteration in binding activity of either 
octamer-binding factor or the unidentified complex c (Fig. 5 
and 7) on wycAP-1 oligo, indicating that any effect exerted 
from myc NRE during differentiation of F412B2TK" cells 
could be explained in terms of FOS/JUN altered levels bound 
to the AP-1 site. 
In previous studies, FOS antibodies and in vitro translated 
FOS and JUN proteins were used to certify that the specific 
factor which binds to the AP-1 site of the NRE of c-myc is a 
FOS/JUN complex (19,26). We showed that JUN antibody 
also inhibits the binding of AP-1 complex to myc NRE (Fig. 
6, lanes 8 and 11), further supporting that the components of 
the nuclear factor with AP-1 binding capacity are the FOS 
and JUN proteins. 
FOS and JUN proteins have been proposed as possible 
contributors to the repression of c-myc, through binding to 
m^c-NRE (19). Reciprocal regulation of c-myc and c-fos has 
been observed during differentiation of a murine myeloid 
leukemia cell line; c-myc expression ceases as those cells 
differentiate, whereas c-fos is activated (32). It has also been 
shown that induction of c-myc by mitogens begins only after 
expression of c-fos begins to decline (33). Similarly, we 
showed that c-myc is down-regulated while c-fos mRNA 
levels become higher in differentiated than non-differentiated 
FL cells (Fig. 2, lanes b and c). Nevertheless, regulation of 
fos and jun expression is complex and both transcriptional 
and post-transcriptional control could contribute to the final 
AP-1 activity (17). Since there is a clear increase in AP-1 
binding to the c-myc AP-1 site (Fig. 7) we propose that 
FOS/JUN complex may contribute to down regulation of c-
myc during the HMBA-induced differentiation of FL cells. 
Furthermore, since the increase of binding is observed during 
the first 3 days of induction, at or before cellular terminal 
division and gene expression (Figs. 2, 4 and 7) we conclude 
that the increased binding of AP-1 followed by a drop on 
days 4 and 5 may contribute to repression of c-myc, which is 
most prominent during the last days of exposure to HMBA, 
and that repression may, in turn, be correlated with the 
terminal differentiation steps. Recent results, suggesting that 
induction to differentiation but not commitment may require 
the late decline in c-myc mRNA, are in agreement with such 
a correlation (28). 
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